INSTITUTE PROFILE
• Founded in 1991
• Biotech/pharmaceutical incubator
• Lab: heart of Silicon Valley, California
• Spun out 17 companies, 6 IPO/exits
• 45,000 sq. ft. lab, offices in Sunnyvale
• 15 scientists; drug development specialists
• Major life science disciplines: Medicinal chemistry,
Pharmacology, Molecular biology, Cell Biology
MISSION STATEMENT
• Panorama identifies, initiates and incubates novel, proprietary bio-medical projects.
• Projects originate from in-house research or by collaboration or license from outside of PRI.
• As projects mature, they may be out-licensed to other companies or provide the basis for a PRI start-up company.
Conception/Initiation Of Pharmaceutical Projects/Molecules
1. Therapeutic human monoclonal antibodies: endotoxin, tetanus, RSV
2. Monocyte colony stimulating factor (CSF1)
3. CAP37, macrophage chemotaxin, wound healing
4. Various TNF inhibitors–organic and protein
5. CAP18/RNIP, lipopolysaccharide binding protein, aka LL-37
6. DHFR inhibitors
7. Cytostatin–glutaminase/asparaginase
8. Radioprotective compounds
9. Diphosphonates
10. MAPPing technology–detection of mRNAs from small #’s of cells using PCR
11. Hepatocyte growth factor
12. Granuloyte colony stimulating factor (G-CSF)
13. Orally active anti-coagulants: poly-sulfated compounds
14. Anti-metastatic enzyme
15. Boronic acid protease inhibitors
16. Plantibodies for enteric infections
17. Novel NMDA receptor blockers
18. Novel neuroprotective compounds
19. Miscellaneous plantibody projects
20. PanozymeTM, VIRILIS®
21. Vaccine for Religious Fundamentalism
22. Trophokines
23. Monobody technology
24. Bi-specific antibodies to target stem cells
25. GTS-21
26. AMS technology
27. Na+/K+ ATPase antibodies for CHF
28. Hepcidin-Fc
29. Prolactin-R antibodies
30. Marinobufogenin (MBG) antibodies
31. Tau antibodies
32. Neurokinin-1 receptor antagonist
33. Somatostatin vaccine for weight gain
34. Novel immunoadhesins (ICAM-1, RAGE, CMG-2)